Changes in ALPP in Women With SUI Following Air Instillation
Primary Purpose
Stress Urinary Incontinence
Status
Completed
Phase
Not Applicable
Locations
Israel
Study Type
Interventional
Intervention
SUI 1
Sponsored by
About this trial
This is an interventional other trial for Stress Urinary Incontinence focused on measuring stress urinary incontinence, abdominal leak point pressure, urodynamic study
Eligibility Criteria
Inclusion Criteria:
- Women
- Age >18 years old
- SUI: pure or stress predominant mixed urinary incontinence.
- Failure of conservative treatment who desires surgical procedure for SUI.
- Signed informed consent for the trial and urodynamic study.
- Negative urine culture.
Exclusion Criteria:
- Neurogenic SUI
- Unable or unwilling to sign informed consent for the trial and urodynamic study.
- Patient who does not will a surgery for SUI
- Prior pelvic or lower abdominal malignancies
- Prior pelvic radiation or surgery except anterior/posterior colporrhaphy or hysterectomy (with or without oophorectomy) for benign disease.
Sites / Locations
- Meir Medical Center
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
SUI 1
Arm Description
Patients will perform urodynamic study before and after instillation of 50 ml of air
Outcomes
Primary Outcome Measures
change in abdominal leak point pressure
to verify the concept of a possible future treatment in the clinical setup by checking physical effect of dumping pressure (decrease in ALLP) by inserting 50 ml of air into the bladder during the urodynamic study in patients with SUI.
Secondary Outcome Measures
adverse events as a measure of safety and tolerability
Full Information
NCT ID
NCT02113670
First Posted
March 28, 2014
Last Updated
October 4, 2017
Sponsor
Meir Medical Center
Collaborators
The Trendlines Group
1. Study Identification
Unique Protocol Identification Number
NCT02113670
Brief Title
Changes in ALPP in Women With SUI Following Air Instillation
Official Title
Changes in Abdominal Leak Point Pressures in Women Stress Urinary Incontinence Following Intravesical Air Instillation During Urodynamic Study
Study Type
Interventional
2. Study Status
Record Verification Date
October 2017
Overall Recruitment Status
Completed
Study Start Date
March 2015 (Actual)
Primary Completion Date
December 31, 2016 (Actual)
Study Completion Date
December 31, 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Meir Medical Center
Collaborators
The Trendlines Group
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
More than 11 million women in the United States suffer from stress urinary incontinence (SUI), the involuntary leakage of urine during everyday activities that put temporary stress on the abdomen and bladder, such as laughing, coughing, and walking. For women with SUI, this pressure often causes urine to leak involuntarily. SUI affects women of all ages including young mothers, pre-menopausal women, and seniors, and can result in significant emotional distress. Current solutions for SUI include disposable pads, behavioral treatment (pelvic floor physical therapy) and surgical intervention. Patients with SUI who failed conservative treatment and wish to be further treated by a surgery may require further work-up by urodynamic study in which abdominal leak point pressures (ALPP) defined and reflect the severity of SUI.
There is continuous need to develop less invasive treatments for SUI that could minimize the use of pads, could be an alternative to painful, costly surgical procedure. The Trendlines Group lab solution is a non-surgical alternative in the treatment of SUI. The concept of the future treatment solution is based on simple physics: injecting a small amount of air into the urinary bladder, which eliminates or greatly reduces involuntary urinary leakage. The air bubble acts as a "shock absorber" to reduce the temporary pressure increase in the bladder that causes urinary leakage. The concept for the new treatment has been tested in a lab environment using lab jig tests and pig urinary system (bladder and urethra). The lab tests showed significant improvement in the bladder pressure when the treatment was implemented by suspending the stress pressure to a level that will not cause urine leakage.
Detailed Description
More than 11 million women in the United States suffer from stress urinary incontinence (SUI), the involuntary leakage of urine during everyday activities that put temporary stress on the abdomen and bladder, such as laughing, coughing, and walking. For women with SUI, this pressure often causes urine to leak involuntarily. SUI affects women of all ages including young mothers, pre-menopausal women, and seniors, and can result in significant emotional distress. Current solutions for SUI include disposable pads, behavioral treatment (pelvic floor physical therapy) and surgical intervention. Patients with SUI who failed conservative treatment and wish to be further treated by a surgery may require further work-up by urodynamic study in which abdominal leak point pressures (ALPP) defined and reflect the severity of SUI.
There is continuous need to develop less invasive treatments for SUI that could minimize the use of pads, could be an alternative to painful, costly surgical procedure. The Trendlines Group lab solution is a non-surgical alternative in the treatment of SUI. The concept of the future treatment solution is based on simple physics: injecting a small amount of air into the urinary bladder, which eliminates or greatly reduces involuntary urinary leakage. The air bubble acts as a "shock absorber" to reduce the temporary pressure increase in the bladder that causes urinary leakage. The concept for the new treatment has been tested in a lab environment using lab jig tests and pig urinary system (bladder and urethra). The lab tests showed significant improvement in the bladder pressure when the treatment was implemented by suspending the stress pressure to a level that will not cause urine leakage.
Following positive results of this proof of concept study we could plan further innovative device to treat SUI in women.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Stress Urinary Incontinence
Keywords
stress urinary incontinence, abdominal leak point pressure, urodynamic study
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
8 (Actual)
8. Arms, Groups, and Interventions
Arm Title
SUI 1
Arm Type
Experimental
Arm Description
Patients will perform urodynamic study before and after instillation of 50 ml of air
Intervention Type
Other
Intervention Name(s)
SUI 1
Other Intervention Name(s)
50ml of air instillation into the bladder
Intervention Description
instillation of 50ml of air into the urinary bladder before the urodynamic test
Primary Outcome Measure Information:
Title
change in abdominal leak point pressure
Description
to verify the concept of a possible future treatment in the clinical setup by checking physical effect of dumping pressure (decrease in ALLP) by inserting 50 ml of air into the bladder during the urodynamic study in patients with SUI.
Time Frame
1 day
Secondary Outcome Measure Information:
Title
adverse events as a measure of safety and tolerability
Time Frame
1 week
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Women
Age >18 years old
SUI: pure or stress predominant mixed urinary incontinence.
Failure of conservative treatment who desires surgical procedure for SUI.
Signed informed consent for the trial and urodynamic study.
Negative urine culture.
Exclusion Criteria:
Neurogenic SUI
Unable or unwilling to sign informed consent for the trial and urodynamic study.
Patient who does not will a surgery for SUI
Prior pelvic or lower abdominal malignancies
Prior pelvic radiation or surgery except anterior/posterior colporrhaphy or hysterectomy (with or without oophorectomy) for benign disease.
Facility Information:
Facility Name
Meir Medical Center
City
Kfar Saba
ZIP/Postal Code
44410
Country
Israel
12. IPD Sharing Statement
Learn more about this trial
Changes in ALPP in Women With SUI Following Air Instillation
We'll reach out to this number within 24 hrs